{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:02:16Z","timestamp":1790118136731,"version":"4.0.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P50-AR052646"],"award-info":[{"award-number":["P50-AR052646"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01-AR083108"],"award-info":[{"award-number":["R01-AR083108"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["P50-HD119693"],"award-info":[{"award-number":["P50-HD119693"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1\u20131,070"],"award-info":[{"award-number":["W81XWH-22-1\u20131,070"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Systemic gene therapies utilizing recombinant adeno-associated virus (rAAV) are in the clinic for the treatment of rare monogenic diseases. This includes delandistrogene moxeparvovec for Duchenne muscular dystrophy (DMD), which uses AAVrh74 vector to deliver a micro-dystrophin transgene to striated muscle. While there have been cases of transformative benefits incurred from rAAV therapies, serious adverse events and mortalities have occurred. This study aimed to investigate short-term rAAV dynamics and long-term systemic responses to intravenous rAAV in the phase 1\/2a delandistrogene moxeparvovec clinical trial (NCT03375164), which represents the most promising cases of micro-dystrophin gene therapy for DMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma and urine specimens from NCT03375164 were analyzed for rAAV using digital PCR and immunoblotting. The integrity and transduction competency of specimen-derived rAAV was evaluated\n                      <jats:italic>in vitro<\/jats:italic>\n                      . Systemic responses to rAAV treatment were investigated using the SomaScan proteomics platform. Preclinical antiviral responses to rAAV were assayed by real-time PCR in the livers of D2.\n                      <jats:italic>mdx<\/jats:italic>\n                      mice 1\u00a0week following systemic treatment with rAAV.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Digital PCR revealed high rAAV content in the plasma at Day 1 following treatment, which substantially reduced by Day 7. Urinary rAAV content was low and variable in all samples tested. The majority of detected vector genomes were packaged in AAVrh74 particles in these specimens, and the vector contained in Day 1 plasma samples was confirmed to be transduction competent. SomaScan data revealed highly significant changes in 99 circulating proteins, which include markers associated with immune activation, interferon responses, complement pathways, and organ injury. Most traditional markers of muscle damage were not changed across the time course, with the limitation that no healthy or untreated DMD samples were analyzed. Features of antiviral and interferon-associated responses were identified in D2.\n                      <jats:italic>mdx<\/jats:italic>\n                      mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Systemic rAAV treatments result in high levels of circulating and transduction-competent vector early after treatment in DMD boys and result in wide-spread activation of immune-associated markers. These findings will provide insights for future investigational study design and efforts to improve safety of rAAV gene therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmmed.2026.1953867","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:10:25Z","timestamp":1790115025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic responses to intravenous rAAV administration in boys with Duchenne muscular dystrophy"],"prefix":"10.3389","volume":"6","author":[{"given":"Brooke E.","family":"Harris","sequence":"first","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]},{"name":"Myology Institute, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke M.","family":"Seldin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]},{"name":"Myology Institute, University of Florida","place":["Gainesville, FL, United States"]},{"name":"Department of Molecular Genetics and Microbiology, University of Florida College of Medicine","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam C.","family":"Towne","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]},{"name":"Myology Institute, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orinda R.","family":"Hobson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]},{"name":"Myology Institute, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Zerpa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]},{"name":"Myology Institute, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Prima","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]},{"name":"Myology Institute, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Lee","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]},{"name":"Myology Institute, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hammers","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Therapeutics, University of Florida College of Medicine","place":["Gainesville, FL, United States"]},{"name":"Myology Institute, University of Florida","place":["Gainesville, FL, United States"]},{"name":"Department of Molecular Genetics and Microbiology, University of Florida College of Medicine","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"39997","DOI":"10.1038\/s41598-025-23758-6","article-title":"Circulating protein biomarkers identified in two independent clinical trial cohorts of glucocorticoid-naive Duchenne muscular dystrophy patients","volume":"15","author":"Ahmadiharchegani","year":"2025","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.biocel.2010.11.005","article-title":"Duchenne muscular dystrophy-what causes the increased membrane permeability in skeletal muscle?","volume":"43","author":"Allen","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pharmthera.2019.02.008","article-title":"Growth differentiation factor 15 (GDF15): a survival protein with therapeutic potential in metabolic diseases","volume":"198","author":"Baek","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.molcel.2010.09.024","article-title":"The nucleolus under stress","volume":"40","author":"Boulon","year":"2010","journal-title":"Mol. Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cmet.2020.10.023","article-title":"GDF-15 neutralization alleviates platinum-based chemotherapy-induced Emesis, anorexia, and weight loss in mice and nonhuman Primates","volume":"32","author":"Breen","year":"2020","journal-title":"Cell Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1016\/j.ymthe.2025.06.032","article-title":"Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy","volume":"33","author":"Byrne","year":"","journal-title":"Mol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-Mediated gene therapy","volume":"33","author":"Byrne","year":"","journal-title":"Mol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0282921","DOI":"10.1128\/mBio.02829-21","article-title":"Human IFIT3 protein induces interferon signaling and inhibits adenovirus immediate early gene expression","volume":"12","author":"Chikhalya","year":"2021","journal-title":"mBio"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/jcb.20030","article-title":"How do glucocorticoids compare to oligo decoys as inhibitors of collagen synthesis and potential toxicity of these therapeutics?","volume":"92","author":"Cutroneo","year":"2004","journal-title":"J. Cell Biochem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1515\/BC.2006.182","article-title":"Human RBM28 protein is a specific nucleolar component of the spliceosomal snRNPs","volume":"387","author":"Damianov","year":"2006","journal-title":"Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng1933","article-title":"Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders","volume":"39","author":"Durand","year":"2007","journal-title":"Nat. Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"101349","DOI":"10.1016\/j.omtm.2024.101349","article-title":"Single cell and TCR analysis of immune cells from AAV gene therapy-dosed Duchenne muscular dystrophy patients","volume":"32","author":"Emami","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41586-023-06921-9","article-title":"GDF15 linked to maternal risk of nausea and vomiting during pregnancy","volume":"625","author":"Fejzo","year":"2024","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/ncb1983","article-title":"UBE2S elongates ubiquitin chains on APC\/C substrates to promote mitotic exit","volume":"11","author":"Garnett","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0089924","DOI":"10.1128\/jvi.00899-24","article-title":"Biophysical and structural insights into AAV genome ejection","volume":"99","author":"Gliwa","year":"2025","journal-title":"J. Virol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e15004","DOI":"10.1371\/journal.pone.0015004","article-title":"Aptamer-based multiplexed proteomic technology for biomarker discovery","volume":"5","author":"Gold","year":"2010","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/jir.2010.0076","article-title":"Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity","volume":"31","author":"Haller","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e003911","DOI":"10.1161\/JAHA.116.003911","article-title":"Tadalafil treatment delays the onset of cardiomyopathy in dystrophin-deficient hearts","volume":"5","author":"Hammers","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.15252\/emmm.201607231","article-title":"Supraphysiological levels of GDF11 induce striated muscle atrophy","volume":"9","author":"Hammers","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"14070","DOI":"10.1038\/s41598-020-70987-y","article-title":"The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy","volume":"10","author":"Hammers","year":"","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e133276","DOI":"10.1172\/jci.insight.133276","article-title":"Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle","volume":"5","author":"Hammers","year":"","journal-title":"JCI Insight"},{"key":"B26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nm0302-253","article-title":"Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy","volume":"8","author":"Harper","year":"2002","journal-title":"Nat. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7153","DOI":"10.1073\/pnas.1507719112","article-title":"Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy","volume":"112","author":"Hathout","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1746363","DOI":"10.3389\/fcell.2025.1746363","article-title":"Impact of follistatin-like 1 on cardiac repair processes following myocardial infarction","volume":"13","author":"He","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1089\/104303402760128513","article-title":"Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy","volume":"13","author":"Herzog","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/rheumatology\/kez078","article-title":"MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis","volume":"58","author":"Huijser","year":"2019","journal-title":"Rheumatol. Oxf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1124\/pr.109.001289","article-title":"Extracellular matrix molecules: potential targets in pharmacotherapy","volume":"61","author":"Jarvelainen","year":"2009","journal-title":"Pharmacol. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1016\/j.xphs.2024.09.006","article-title":"Immunogenicity risk assessment of empty capsids present in adeno-associated viral vectors using predictive innate immune responses","volume":"113","author":"Jarvi","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12014-023-09412-1","article-title":"Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers","volume":"20","author":"Johansson","year":"2023","journal-title":"Clin. Proteomics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2025.03.037","article-title":"The curious case of AAV immunology","volume":"33","author":"Keeler","year":"2025","journal-title":"Mol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.4049\/jimmunol.139.12.4129","article-title":"Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells","volume":"139","author":"Knudsen","year":"1987","journal-title":"J. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1073\/pnas.85.4.1204","article-title":"Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA","volume":"85","author":"Lee","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13395-026-00419-4","article-title":"Functional and structural pathologies in skeletal muscle of a rat model of Duchenne muscular dystrophy","volume":"16","author":"Lee","year":"2026","journal-title":"Skelet. Muscle"},{"key":"B39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting report: 2022 muscular dystrophy association summit on 'safety and challenges in gene transfer therapy","volume":"10","author":"Lek","year":"","journal-title":"J. Neuromuscul. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"22143602261424971","DOI":"10.1177\/22143602261424971","article-title":"Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy","author":"Leon-Astudillo","year":"2026","journal-title":"J. Neuromuscul. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"101524","DOI":"10.1016\/j.jbc.2021.101524","article-title":"RNA-Binding protein RBM28 can translocate from the nucleolus to the nucleoplasm to inhibit the transcriptional activity of p53","volume":"298","author":"Lin","year":"2022","journal-title":"J. Biol. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"eaaz3267","DOI":"10.1126\/scitranslmed.aaz3267","article-title":"Autism-associated SHANK3 mutations impair maturation of neuromuscular junctions and striated muscles","volume":"12","author":"Lutz","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41594-020-0424-6","article-title":"Ubiquitin chain-elongating enzyme UBE2S activates the RING E3 ligase APC\/C for substrate priming","volume":"27","author":"Martinez-Chacin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.ymthe.2026.01.004","article-title":"Incidence, timing, and clinical significance of adverse immune events after gene replacement therapy: a systematic review and meta-analysis","volume":"34","author":"Maurizi","year":"2026","journal-title":"Mol. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"B48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/mus.70276","article-title":"Five-year outcomes with delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy: a phase 1\/2a study","volume":"74","author":"Mendell","year":"2026","journal-title":"Muscle Nerve"},{"key":"B50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s1474-4422(26)00036-0","article-title":"Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study","volume":"25","author":"Muntoni","year":"2026","journal-title":"Lancet Neurology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fphys.2015.00059","article-title":"Role of E2-Ub-conjugating enzymes during skeletal muscle atrophy","volume":"6","author":"Polge","year":"2015","journal-title":"Front. Physiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","article-title":"Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy","volume":"15","author":"Potter","year":"2025","journal-title":"Sci. Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"101216","DOI":"10.1016\/j.omtm.2024.101216","article-title":"B cell focused transient immune suppression protocol for efficient AAV readministration to the liver","volume":"32","author":"Rana","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/10430342251385586","article-title":"Enhancing AAV9-UFmuDys1 gene therapy efficacy through immunosuppression in mice with pre-existing immunity and enabling redosing strategies for Duchenne muscular dystrophy","volume":"37","author":"Saha","year":"2026","journal-title":"Hum. Gene Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e173510","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Invest."},{"key":"B57","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","article-title":"Interferon-stimulated genes and their antiviral effector functions","volume":"1","author":"Schoggins","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1128\/mcb.8.10.4518-4523.1988","article-title":"Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation","volume":"8","author":"Staeheli","year":"1988","journal-title":"Mol. Cell Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1078\/0171-9335-00256","article-title":"Activated leukocyte cell adhesion molecule (CD166\/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration","volume":"81","author":"Swart","year":"2002","journal-title":"Eur. J. Cell Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0293277","DOI":"10.1371\/journal.pone.0293277","article-title":"A novel method for quantitation of AAV genome integrity using duplex digital PCR","volume":"18","author":"Tereshko","year":"2023","journal-title":"PLoS One"},{"key":"B61","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.molimm.2021.10.010","article-title":"Circulating C1q levels in health and disease, more than just a biomarker","volume":"140","author":"van de Bovenkamp","year":"2021","journal-title":"Mol. Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e2031851","DOI":"10.1001\/jamanetworkopen.2020.31851","article-title":"Assessment of rAAVrh.74.MHCK7.micro-dystrophin gene therapy using magnetic resonance imaging in children with Duchenne muscular dystrophy","volume":"4","author":"Willcocks","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B63","doi-asserted-by":"publisher","first-page":"101551","DOI":"10.1016\/j.omtm.2025.101551","article-title":"Innate immune response to AAV-Based gene therapy vectors: mechanisms of complement activation and cytokine release","volume":"33","author":"Xicluna","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3724\/abbs.2024062","article-title":"UBE2C promotes myoblast differentiation and skeletal muscle regeneration through the akt signaling pathway","volume":"56","author":"Yuan","year":"2024","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"}],"container-title":["Frontiers in Molecular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2026.1953867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:10:27Z","timestamp":1790115027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmmed.2026.1953867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":64,"alternative-id":["10.3389\/fmmed.2026.1953867"],"URL":"https:\/\/doi.org\/10.3389\/fmmed.2026.1953867","relation":{},"ISSN":["2674-0095"],"issn-type":[{"value":"2674-0095","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1953867"}}